During the past decade, JSC Evex Hospitals conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 2 clinical trials were completed, i.e. on average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 2 clinical trials were completed. i.e. 22.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "JSC Evex Hospitals" #1 sponsor was "Alvotech Swiss AG" with 2 trials, followed by "Pfizer" with 2 trials sponsored, "Bayer" with 1 trials sponsored, "Destiny Pharma Plc" with 1 trials sponsored and "EMD Serono Research & Development Institute, Inc." with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "JSC Evex Hospitals" #1 collaborator was "GORTEC (Head and Neck Oncology and Radiotherapy Group)" with 1 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator and "Regeneron Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "JSC Evex Hospitals" are "Arthritis, Psoriatic" (1 trials), "Chronic Gout" (1 trials), "Gastroesophageal Reflux Disease" (1 trials), "Immunoglobulin A (IgA) Nephropathy" (1 trials) and "Neovascular (Wet) AMD" (1 trials). Many other conditions were trialed in "JSC Evex Hospitals" in a lesser frequency.

Most popular intervention types in "JSC Evex Hospitals" are "Drug" (9 trials), "Other" (2 trials), "Combination Product" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "AVT06 (proposed aflibercept biosimilar)" (1 trials), "Adalimumab" (1 trials), "Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)" (1 trials) and "Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)" (1 trials). Other intervention names were less common.

The vast majority of trials in "JSC Evex Hospitals" are 10 trials for "All" genders.

Currently, there are NaN active trials in "JSC Evex Hospitals". undefined are not yet recruiting, 3 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in JSC Evex Hospitals, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in JSC Evex Hospitals, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".